SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

31 Jan 2026 Evaluate
The quarter ended December 2025 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 5536.32 millions.The Total revenue for the quarter ended December 2025 of  Rs. 1218.95  millions  grew by 716.01% from Rs. 149.38 millions.Operating Profit saw a handsome growth to 1844.42 millions from 765.25 millions in the quarter ended December 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 5536.32 5509.17 0.49 15744.00 15834.65 -0.57 21394.23 18661.17 14.65
Other Income 1032.43 24.28 4152.18 1190.93 340.66 249.59 461.88 587.11 -21.33
PBIDT 1844.42 765.25 141.02 3297.46 2285.76 44.26 3086.30 2092.16 47.52
Interest 272.45 342.14 -20.37 871.06 1165.52 -25.26 1459.12 1393.77 4.69
PBDT 1571.97 422.94 271.68 2426.40 1119.97 116.65 1626.91 644.74 152.34
Depreciation 223.95 209.18 7.06 660.47 622.37 6.12 846.08 874.07 -3.20
PBT 1348.02 213.76 530.62 1765.93 497.60 254.89 780.83 -229.33 -440.48
TAX 129.07 64.38 100.48 93.11 67.32 38.31 189.27 13.42 1310.36
Deferred Tax -98.72 7.03 -1504.27 -20.52 29.60 -169.32 203.91 14.61 1295.69
PAT 1218.95 149.38 716.01 1672.82 430.28 288.77 591.56 -242.75 -343.69
Equity 921.73 921.63 0.01 921.73 921.63 0.01 921.63 919.00 0.29
PBIDTM(%) 33.31 13.89 139.84 20.94 14.44 45.09 14.43 11.21 28.67

Strides Pharma Scien Share Price

1036.35 -16.90 (-1.60%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×